CN113368209B - New use of QIZHI Capsule in preparing medicine for treating essential hypertension - Google Patents

New use of QIZHI Capsule in preparing medicine for treating essential hypertension Download PDF

Info

Publication number
CN113368209B
CN113368209B CN202110641504.1A CN202110641504A CN113368209B CN 113368209 B CN113368209 B CN 113368209B CN 202110641504 A CN202110641504 A CN 202110641504A CN 113368209 B CN113368209 B CN 113368209B
Authority
CN
China
Prior art keywords
leech
astragalus
parts
capsule
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110641504.1A
Other languages
Chinese (zh)
Other versions
CN113368209A (en
Inventor
王喜军
闫广利
孙辉
杨乐
白璧炜
车延柠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin traditional Chinese medicine four factory Co.,Ltd.
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110641504.1A priority Critical patent/CN113368209B/en
Publication of CN113368209A publication Critical patent/CN113368209A/en
Application granted granted Critical
Publication of CN113368209B publication Critical patent/CN113368209B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/902—Sparganiaceae (Bur-reed family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Insects & Arthropods (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The invention discloses a new application of astragalus and leech capsules in preparing a medicament for treating primary hypertension. The astragalus and leech capsule consists of astragalus, polygonum multiflorum, cassia seed, hawthorn, peach kernel, rhizoma curcumae, rhizoma sparganii, leech and ground beetle, and the traditional Chinese medicines are mutually required and mutually matched, and accord with the compatibility principle of monarch, minister, assistant and guide, and have the functions of tonifying qi, removing blood stasis and dredging collaterals. Experiments prove that the astragalus and leech capsule treatment can lead the hypertension to continuously and stably drop and obviously restore the whole metabolic function of the organism, and is an effective medicament for treating the primary hypertension.

Description

New use of QIZHI Capsule in preparing medicine for treating essential hypertension
Technical Field
The invention relates to a new application of astragalus and leech capsules in preparing a medicament for treating primary hypertension, and belongs to the technical field of application of traditional Chinese medicines.
Background
The primary hypertension is a comprehensive disease which is mainly characterized by the rise of systemic arterial pressure and is caused by decompensation of the normal blood pressure regulating mechanism of an organism under the action of a plurality of acquired environmental factors under a certain genetic background. The primary hypertension accounts for more than 95% of the total blood pressure, is a primary risk factor for inducing cardiovascular and cerebrovascular events of people, effectively controls the blood pressure and treats the primary hypertension, and is an important medical problem for maintaining human health.
The chemical medicine is the main medicine for treating hypertension clinically at present due to the characteristics of clear action mechanism, quick effect and strong action, and comprises a calcium channel blocker, an angiotensin converting enzyme inhibitor, an angiotensin receptor antagonist, a diuretic and a beta receptor blocker. In order to fully exert the complementary action mechanism of the medicines to increase the curative effect, lead the blood pressure to reach the standard rapidly, reduce the contraindications, the discomforts and the side effects generated in the single administration process and keep the longer action time, the combined application of the antihypertensive medicines has become a basic method of antihypertensive treatment (revised committee of China guidelines for controlling hypertension, 2018 revised edition of China guidelines for controlling hypertension, cardiovascular and cerebrovascular diseases control, 2019.19 (1): 1-44.). Thus, the compound preparation with fixed proportion (CN 105832731B, CN103239723B, CN 102008711B) comprising the medicines is invented.
However, primary hypertension is a complex disease with the combined action of genetic factors and acquired environmental factors, chemical drugs mainly aim at a certain link of pathological changes in the incidence process of hypertension, and the action route and the action target point are relatively single, so that the rapid depressurization can be realized, but the blood pressure management is complex, and the improvement of hypertension complications cannot be considered. The traditional Chinese medicine is used for treating hypertension from multiple components, multiple links and multiple targets by treating based on dialectical theory, regulating yin-yang balance and deficiency and excess of qi and blood of the organism, and correcting organism dysfunction. The prescription (Chinese herbal compound) is a medicine clinically used in traditional Chinese medicine, and is formed by combining a plurality of traditional Chinese medicines through 'seven emotions and combination' and 'monarch, minister, assistant and guide'; the single Chinese medicine is only the raw materials composing the prescription, and the curative effect of the Chinese medicine is expressed by aiming at the symptoms of the prescription. Therefore, the traditional Chinese medicine compound is used for treating hypertension, on one hand, the prescription function is not only simple addition of the blood pressure reducing effect of single traditional Chinese medicine, but also the integral effect of a plurality of traditional Chinese medicines on the pharmacological effect; on the other hand, the traditional Chinese medicines composing the prescription do not have pharmacological effects of reducing blood pressure. The invention discloses a astragalus and leech capsule which has obvious effect of treating primary hypertension, and the prescription consists of astragalus, leech, ground beetle, peach kernel, rhizoma sparganii, rhizoma curcumae, hawthorn, cassia seed, polygonum multiflorum and other traditional Chinese medicines, and has the functions of tonifying qi, removing blood stasis and treating the channel.
The astragalus and leech capsule is produced by four factories of Harbin traditional Chinese medicines, the national medicine standard number implemented nowadays is WS-5431 (B-0431) -2014Z, and the approved functions and indications are tonifying qi, removing blood stasis and dredging collaterals, and are clinically used for treating hyperlipidemia and qi deficiency and blood stasis. Through clinical research in recent years, the application range of the astragalus-leech capsule is further expanded, and the literature reports that satisfactory clinical observation of the astragalus-leech capsule for treating stable angina pectoris is obtained (Peng Cailiang, et al, clinical observation of the astragalus-leech capsule for treating stable angina pectoris [ J ] Heilongjiang traditional Chinese medicine, 2014, 5:14-15.). The invention discovers a new application of the astragalus and leech capsule in treating primary hypertension through experimental research.
The invention discloses a new application of astragalus and leech capsules in a medicament for treating primary hypertension. The astragalus and leech capsule consists of astragalus, polygonum multiflorum, cassia seed, hawthorn, peach kernel, rhizoma curcumae, rhizoma sparganii, leech, ground beetle and other medicinal herbs, and the traditional Chinese medicines are mutually required and mutually matched, and accord with the compatibility principle of monarch, minister, assistant and guide, and have the functions of tonifying qi, removing blood stasis and dredging collaterals. Experiments prove that the astragalus and leech capsule treatment can lead the hypertension to continuously and stably drop and obviously restore the whole metabolic state of the organism, and is an effective medicament for treating the primary hypertension.
Disclosure of Invention
The invention aims to solve the technical problems in the prior art, and provides a new application of astragalus and leech capsules in preparing medicaments for treating primary hypertension, so as to overcome the defects in the prior art.
In order to solve the technical problems, the invention adopts the following technical scheme:
a new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
The astragalus and leech capsules can obviously reduce the systolic blood pressure of the primary hypertension.
The QIZHI capsule can regulate physiological functions of the body of the primary hypertension.
The physiological functions of the body include increasing body weight, and restoring (i.e., reducing) the metabolic rate of the body.
The dosage of the astragalus and leech capsules is 1 to 4 times of the dosage for clinically treating the hyperlipidemia.
The astragalus and leech capsules are prepared from the following raw material medicines in parts by weight: 100 to 400 parts of astragalus, 40 to 160 parts of leech, 75 to 300 parts of peach kernel, 75 to 300 parts of fleece-flower root, 55 to 220 parts of rhizoma zedoariae, 55 to 220 parts of rhizoma sparganii, 62.5 to 250 parts of semen cassiae, 62.5 to 250 parts of hawthorn and 15 to 60 parts of ground beetle.
The astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of semen cassiae, 125 parts of hawthorn and 30 parts of ground beetle.
The preparation method of the astragalus and leech capsules comprises the following steps:
firstly, weighing leech, rhizoma curcumae and rhizoma sparganii according to a proportion, and crushing the leech, the rhizoma curcumae and the rhizoma sparganii into fine powder;
weighing astragalus root, peach kernel, fleece-flower root, cassia seed, haw and ground beetle according to a proportion, adding water for decoction twice, adding 10 times of water for the first time and adding 8 times of water for the second time, decocting for 2 hours each time, merging decoction, filtering, and concentrating filtrate to thick paste with the relative density of 1.30-1.35;
and thirdly, taking the fine powder in the first step, adding the thick paste in the second step, uniformly mixing, drying at 50-60 ℃, crushing and encapsulating.
The relative density is 1.30-1.35 at 80 ℃.
The astragalus and leech capsules can be replaced by granules, tablets, powder or pills.
The invention discloses a astragalus and leech capsule for treating primary hypertension, which has the characteristics of mutual Chinese medicine and mutual compatibility and the principle of monarch, minister, assistant and guide compatibility of prescriptions. The astragalus root is used for tonifying qi and raising yang, and aims at invigorating qi, promoting blood circulation, removing blood stasis and dredging collaterals, and is a monarch drug; leech and ground beetle are used for breaking blood, removing stasis and eliminating mass, zedoary and rhizoma sparganii are used for breaking blood, removing stasis, eliminating mass and removing accumulation, promoting qi circulation and relieving pain, peach kernel is used for breaking blood, removing stasis and moistening dryness, and three groups of blood-breaking and stasis-removing herbs are further used for being matched with qi-supplementing medicines such as astragalus root, so that deficiency can be treated and blood stasis can not be kept for a long time, and the three groups of blood-breaking and stasis-removing herbs are ministerial medicines; the polygonum multiflorum detoxifies, loosens the bowel to relieve constipation, the semen cassiae clears heat, loosens the bowel to relieve constipation, the hawthorn fruit moves qi to dissipate blood stasis, three herbs are mutually required, and the three herbs are combined with blood stasis-breaking and removing herbs to promote blood stasis and promote tissue regeneration, so that the medicine is a guiding drug; the formula of the medicine for invigorating qi is compatible with a plurality of medicines for breaking blood and removing stasis, and medicines for reducing turbid and expelling toxin, so that qi is overabundant and blood is moved, stasis is removed and collaterals are dredged, qi is supplemented without stagnation, blood is broken without hurting positive, and the medicines are combined to play roles of tonifying qi, removing stasis and dredging collaterals together, and the medicine is used for treating primary hypertension qi deficiency and blood stasis syndrome.
The invention discloses a new application of astragalus and leech capsules in preparing medicaments for treating primary hypertension, wherein the medicament form also comprises one of granules, powder, tablets and pills, and pharmaceutically acceptable auxiliary materials such as fillers of starch, lactose, mannose, chitin, microcrystalline cellulose, sucrose and the like are required to be added in the preparation of the medicament form in order to realize the preparation of the medicament form; disintegrating agents such as starch, microcrystalline cellulose, crosslinked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, and crosslinked sodium carboxymethyl cellulose; lubricants such as magnesium stearate, sodium lauryl sulfate, talc, and silica; binding agents such as starch slurry, polyvinylpyrrolidone, and hydroxypropyl methylcellulose; saccharin sodium, aspartame, sucrose, sodium cyclamate, etc.
The novel application of the astragalus and leech capsules disclosed by the invention in preparing the medicine for treating the primary hypertension has the remarkable advantages that: (1) unlike other invention patents which treat liver-yang hyperactivity (CN 1283275C), yin deficiency and yang hyperactivity (CN 103127421B), liver-kidney yin deficiency (CN 103989817B), phlegm-damp obstruction (CN 105213822B) and the like, the invention adopts the treatment methods of tonifying qi, removing blood stasis and dredging collaterals to form astragalus and leech capsules aiming at primary hypertension and blood stasis pathogenesis; (2) the astragalus and leech capsule prescription composition accords with the compatibility theory of monarch, minister, assistant and guide and seven emotions and combination of the traditional Chinese medicine prescription, and qi-tonifying medicaments are compatible with blood-breaking and stasis-removing medicaments and turbidity-reducing and toxin-removing medicaments, the blood-breaking and stasis-removing medicaments and the turbidity-reducing and toxin-removing medicaments are mutually compatible, the qi-tonifying medicaments are monarch medicaments, the blood-breaking and stasis-removing medicaments are minister medicaments, the turbidity-reducing and toxin-removing medicaments are assistant medicaments, so that qi is overactive, blood is enabled, blood is stasis is removed, and collaterals are removed, and the astragalus and leech capsule is used for treating primary hypertension qi deficiency and blood stasis symptoms; (3) animal experiments prove that the astragalus and leech capsule can not only smoothly and remarkably reduce the blood pressure by more than 30mmHg in a treatment period of 4 weeks, and the blood pressure reduction amplitude is superior to that of the traditional Chinese medicine composition for treating the hyperbaric rats by the methods (1), but also can restore the metabolic network and the body weight of the hyperbaric rats to normal level, thus being beneficial to restoring the whole physiological function of organisms and reflecting the whole treatment advantage of the traditional Chinese medicine.
Drawings
FIG. 1 is a graph showing the trend of systolic blood pressure change of rats in the model group (SHR group) and normal control group (WKY group) at 4-13 weeks of age (P <0.01 compared with the normal control group);
FIG. 2 is a graph showing the trend of systolic blood pressure change of rats in the model control group (SHR group), normal control group (WKY group), high-dose Qilder capsule group, medium-dose Qilder capsule group, low-dose Qilder capsule group, and aspirin control group at 13-17 weeks of age (compared with the normal control group, # P <0.01; compared with the model control group, # P < 0.01);
fig. 3 is a graph showing the trend of weight change of rats in the model control group (SHR group) and normal control group (WKY group) of the present invention at 4-13 weeks of age (P <0.01, P <0.05 compared to the normal control group).
Fig. 4 is a graph showing the trend of weight change of rats in the model control group (SHR group), normal control group (WKY group), high-dose astragalus-leech capsule group, medium-dose astragalus-leech capsule group, low-dose astragalus-leech capsule group, aspirin control group at 13-17 weeks of age (P <0.01 compared with the normal control group; compared with the model control group, ## P＜0.01)。
fig. 5 is a score of PCA analysis of the urinary metabolic network of rats treated with the astragalus and leech capsule according to the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more clear, the present invention will be described in further detail with reference to the accompanying drawings and examples. The specific embodiments described herein are to be considered in an illustrative sense only and are not intended to limit the invention.
Example 1:
a new use of QIZHI Capsule in preparing medicine for treating essential hypertension is provided.
The astragalus and leech capsules can obviously reduce the systolic blood pressure of the primary hypertension.
The QIZHI capsule can regulate physiological functions of the body of the primary hypertension.
The physiological functions of the organism comprise increasing weight and restoring the metabolic network of the organism.
The dosage of the astragalus and leech capsules is 1 to 4 times of the dosage for clinically treating the hyperlipidemia.
The astragalus and leech capsule comprises 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of polygonum multiflorum, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of semen cassiae, 125 parts of hawthorn and 30 parts of ground beetle.
The preparation method of the astragalus and leech capsules comprises the following steps:
firstly, weighing leech, rhizoma curcumae and rhizoma sparganii according to a proportion, and crushing the leech, the rhizoma curcumae and the rhizoma sparganii into fine powder;
weighing astragalus root, peach kernel, fleece-flower root, cassia seed, haw and ground beetle according to a proportion, adding water for decoction twice, adding 10 times of water for the first time and adding 8 times of water for the second time, decocting for 2 hours each time, merging decoction, filtering, and concentrating filtrate to thick paste with the relative density of 1.30-1.35;
and thirdly, taking the fine powder in the first step, adding the thick paste in the second step, uniformly mixing, drying at 50-60 ℃, crushing and encapsulating.
The relative density is 1.30-1.35 at 80 ℃.
The astragalus and leech capsules can be replaced by granules, tablets, powder or pills.
The effect of the astragalus and leech capsules of the invention in treating essential hypertension is further illustrated by the following experiments.
The primary hypertension rat (Spontaneous Hypertension Rat, SHR) is a hereditary hypertension model rat, the pathogenesis and development changes are close to those of human beings, and the blood pressure level is higher and stable, so that the model is an animal model of hypertension which is internationally recognized at present. The experiment adopts the animal model to research the regulation and control of the astragalus and leech capsules on hypertension, and the antihypertensive effect and intensity of the astragalus and leech capsules are clear. And the metabolic network of the SHR rats before and after the treatment of the astragalus and bdellovibro capsules is analyzed by utilizing a metabonomics technology, so that the regulation and control of the whole function of the primary hypertension rat model by the medicament is illustrated from the aspect of a system.
1. Experimental materials
1. Instrument for measuring and controlling the intensity of light
Constant temperature noninvasive blood pressure measuring instrument (ZH 200, anhua Zhenghua biological instrument Co., ltd.); ultra-high performance liquid chromatography (acquisition UPLC, waters, USA); high resolution mass spectrometer (Synapt G2/Si-HDMS, waters, USA); histology data processing software Progenisis QI (Waters company, usa).
2. Reagent
Astragalus and leech capsules (supplied by four factories of Harbin traditional Chinese medicines), aspirin effervescent tablets (0.1 g in specification, aoshikang pharmaceutical Co., ltd.) and sodium carboxymethyl cellulose (Tianjin far chemical reagent Co., ltd.).
3. Experimental animal
Primary hypertensive rats (SHR), male; the normal blood pressure control animals of WKY rats, males and SHR are control strains of hypertensive rats, and are provided by Beijing Vetong Lihua laboratory animal technology Co., ltd., license number: SCXK (jing) 2016-006. The raising temperature is 24+/-2 ℃, the humidity is 65% -75%, the light is shielded for 12 hours, the light is illuminated for 12 hours, and drinking water is fed freely.
2. Experimental method
1. Preparation of dosing samples
1.1 preparation of gastric juice for drug infusion of Qiydella capsules
Weighing three parts of astragalus and leech capsule content fine powder: 32.4g, 64.8g and 129.6g are respectively and evenly mixed with 1000mL of sodium carboxymethylcellulose (CMC-Na) solution to prepare astragalus-leech capsule medicines with the concentration of 32.4mg/mL, 64.8mg/mL and 129.6mg/mL, and gastric juice is respectively 1, 2 and 4 times of the dosage of the astragalus-leech capsule approved clinical treatment of hyperlipidemia.
1.2 preparation of aspirin gastric juice
The common dosage of aspirin anticoagulation is 100 mg/day, and the dosage of aspirin is converted into the dosage of rats by 2 times of the dosage, so as to prepare the aspirin gastric lavage fluid. 36 aspirin effervescent tablets (each tablet contains 0.1g of aspirin) are taken and put into 20mL of distilled water, CMC-Na solution is slowly added after the aspirin effervescent tablets are completely dissolved, the mixture is continuously stirred until the solution is uniform, the volume is fixed to 1000mL, and the aspirin gastric lavage liquid with the concentration of 3.6mg/mL is prepared.
2. Grouping and administration of laboratory animals
40 male SHR rats were randomly divided into 5 groups of 8: model control group, high-dose administration group of astragalus and leech capsule, low-dose administration group of astragalus and leech capsule and aspirin administration group. Male WKY rats 8 were normal control group. Each group of rats was normally fed from week 4; from the 13 th week of age, rats in each administration group were given the corresponding drug gastric juice by 1.0mL/100g gastric lavage, and the normal control group and model control group rats were given the corresponding doses of CMC-Na solution by gastric lavage for 4 weeks. The normal control group was WKY rats, male.
3. Determination of blood pressure and body weight
Systolic blood pressure was measured noninvasively using the rat tail arterial blood pressure analysis system. Normal control and model control rats were tested weekly for tail artery systolic blood pressure and body weight starting at week 4; the rat tail systolic pressure and body weight of each of the administration groups were measured from week 13.
4. Determination of the urine Metabolic network
4.1 collection and processing of urine samples
The rats were harvested for 14-17 weeks of age, urine was collected for 12 hours at night each week, centrifuged (4 ℃,13000r/min,10 min) after harvesting, and stored at-80 ℃. Thawing at room temperature before sample analysis, diluting with distilled water for 1 time, swirling for 10s, centrifuging (4 ℃ C., 13000r/min,10 min), and collecting supernatant for UPLC-G2-Si-HDMS analysis.
4.2 analysis conditions
4.2.1 chromatographic conditions
Chromatographic column: waters ACQUITY UPLC TM HSS T3 (100 mm. Times.2.1 mm,1.8 μm); mobile phase a:0.1% acetonitrile formate solution, mobile phase B:0.1% aqueous formic acid, linear gradient elution procedure is shown in table 1; column temperature: 45 ℃; sample injection amount: 1 mul.
TABLE 1 UPLC mobile phase gradient elution method for rat urine sample
Figure BDA0003108013160000081
4.2.2 Mass Spectrometry conditions
Electrospray ion source (ESI); capillary voltage 2500V; taper hole voltage 40V; ion source temperature: 110 ℃; extracting taper hole voltage of 5.0V; the desolventizing gas temperature is 400 ℃; the air flow of the taper hole is 50L/h; the flow rate of the desolventizing agent is 800L/h; leucine-enkephalin is adopted for accurate quality determination; mass scan range: 50-1200Da.
2. Experimental results
1. Blood pressure changes
The changes in systolic blood pressure of the rats in the model group and normal control group before the administration of the treatment are shown in Table 2 and FIG. 1. The systolic blood pressure of the normal control group rats does not change significantly during 4-13 weeks of age; the model rats were significantly higher in systolic blood pressure than the normal control (P < 0.01) from 5 weeks of age to an average systolic blood pressure rise of 193.15 ±4.52mmHg at 13 weeks of age, compared to normal control rats.
Table 2 changes in 4-13 week old systolic blood pressure (mmHg) (mean.+ -. Standard deviation, n=8)
Figure BDA0003108013160000082
Note that: * P <0.05, P <0.01.
The changes in blood pressure of the rats in the model group and the normal control group after the administration of the treatment are shown in Table 3 and FIG. 2. The shrinkage pressure of the rats in the model group of 13-17 weeks old continues to rise, and the average shrinkage pressure is 202.41 +/-3.35 mmHg at 17 weeks old; the normal control rats had no significant change in systolic blood pressure and had an average systolic blood pressure of 128.33.+ -. 5.68mmHg. In each administration group, the high, medium and low doses of astragalus and leech capsules can obviously reduce the contraction pressure of rats, and after one week of administration, the three groups of rats have obvious curative effects, and the contraction pressure of the rats is obviously reduced compared with that of a model group (P < 0.01). The high-dose antihypertensive effect of the astragalus and leech capsules is best, the effect is obviously lower than that of a model group (P < 0.01) in 1 week, and the average systolic pressure drop is 163.75 +/-9.95 mmHg in 4 weeks of administration treatment; the dose antihypertensive effect in the astragalus and leech capsules is only inferior to that of high dose, the effect is obviously lower than that of a model group (P < 0.01) in 1 week of treatment, and the average shrinkage pressure of rats is reduced to 165.83 +/-7.37 mmHg in 4 weeks of treatment; the low-dose antihypertensive effect of the astragalus and leech capsules is lower than that of high and medium doses, but the systolic pressure (P < 0.01) of rats is obviously reduced in 1 week, and the average systolic pressure is reduced to 174.83 +/-3.77 mmHg in 4 weeks of treatment. The aspirin control group had no significant difference in systolic blood pressure between the treatment period of 2 weeks and the treatment period of 4 weeks, which was significantly lower than that of the model group (P < 0.01), and the mean systolic blood pressure of 4 weeks was 190.16.+ -. 1.57mmHg. The result shows that aspirin with the pharmacological actions of inhibiting platelet aggregation and resisting thrombus can not effectively reduce blood pressure, while the traditional Chinese medicine compound astragalus and leech capsule with the functions of tonifying qi, removing blood stasis and dredging collaterals can effectively reduce blood pressure, so that the astragalus and leech capsule has a special blood pressure reducing effect.
Table 3 comparison of changes in systolic blood pressure (mmHg) in rats aged 13-17 weeks (mean.+ -. Standard deviation, n=8)
Figure BDA0003108013160000091
Note that: p <0.05, P <0.01 compared to normal control; compared to the model control group, #p <0.05, #p <0.01.
2. Weight change
The body weight changes of rats in the model group and normal control group before the administration of the treatment are shown in Table 4 and FIG. 3. Model group rats steadily increased in weight at 5-10 weeks of age, and increased at a rate greater than that of the blank group, and at 10 weeks of age, the model group rats decreased in weight at a rate significantly lower than that of the blank group at 13 weeks of age.
Table 4 comparison of the body weight (g) changes (mean.+ -. Standard deviation, n=8) of rats of each group at 4-13 weeks of age
Figure BDA0003108013160000101
Note that: p <0.05, P <0.01 compared to normal control.
The change in body weight of rats in the model group and normal control group after the administration of the treatment is shown in table 5 and fig. 4. At the beginning of the 13 week old dosing, rats in each dosing group had no significant difference in weight compared to the model group, which was within the range of 244.46 ±9.40g, but significantly lower than the normal control group (P < 0.01). Rats in the group administered with QIZHI capsule at 13-17 weeks of age had a higher rate of weight gain than the model group, tending to the normal control group. At 17 weeks of age, rats in each dosing group of Qihe capsules had a higher body weight than the model group, with a very significant difference (P < 0.01), approaching the normal control group. The body weight of the rats of the 13-17 week old aspirin administration group is not significantly different from that of the model group.
Table 5 comparison of the changes in body weight (g) of rats of each group at 13-17 weeks of age (mean.+ -. Standard deviation D, n=8)
Figure BDA0003108013160000102
Figure BDA0003108013160000111
Note that: p <0.05, P <0.01 compared to normal control; compared to the model group, #p <0.05, #p <0.01.
3. Regulation of metabolic network in primary hypertensive rats
The blood pressure lowering measurement result shows that the high dose of the astragalus-leech capsules has better blood pressure lowering effect, and metabolic network analysis is carried out by selecting the high dose group of the astragalus-leech capsules, the model control group and the blank control group for more clearly showing the change of the metabolic network of the rats. The urine of the high-dose group, the model control group and the normal control group of the astragalus and leech capsules are analyzed by utilizing the condition of urine metabolite fingerprint analysis, UPLC-Q/TOF-MS data of the urine of rats in each group are measured, metabolite retention time, m/z and peak intensity data are extracted by utilizing the histology data processing software Progenesis QI (Waters company, USA), principal Component Analysis (PCA) is carried out, and a score graph (score Plot) reflecting the change of the metabolic network of the organism is obtained as shown in figure 5. Each point in the figure represents each rat, and its position in the figure represents the spatial state of the metabolic network of that rat; in the figure, the point C represents a normal control group rat, the point M represents a model control group rat, the point QH represents a Qh capsule high-dose group rat, the point C and the point QH are gathered into one type, the point M is gathered into one type, the condition that the metabolic network of the hypertension rat disorder is called back to the normal rat after the Qh capsule treatment is shown, the Qh capsule can restore the physiological function of the organism to the normal level while reducing the blood pressure, and the change of the body weight of the rat is combined, so that the Qh capsule can not only reduce the blood pressure, but also restore the whole physiological function of the organism.
4. Conclusion(s)
The study utilizes a primary hypertension rat model to evaluate the treatment effect of the astragalus-leech capsules on hypertension, and shows that the astragalus-leech capsules can obviously reduce the blood pressure of the primary hypertension rat, obviously increase the weight of the hypertension rat and regulate the metabolic network of the hypertension rat body, and can effectively treat the primary hypertension and regulate the overall physiological function of hypertension.
Example 2:
this embodiment differs from embodiment 1 only in that: the astragalus and leech capsule is prepared from the following raw materials in parts by weight: 100 parts of astragalus, 40 parts of leech, 75 parts of peach kernel, 75 parts of fleece-flower root, 55 parts of rhizoma curcumae, 55 parts of rhizoma sparganii, 62.5 parts of semen cassiae, 62.5 parts of hawthorn and 15 parts of ground beetle.
Example 3:
this embodiment differs from embodiment 1 only in that: the astragalus and leech capsule is prepared from the following raw materials in parts by weight: 400 parts of astragalus, 160 parts of leech, 300 parts of peach kernel, 300 parts of fleece-flower root, 20 parts of curcuma zedoary, 220 parts of rhizoma sparganii, 250 parts of semen cassiae, 250 parts of hawthorn and 60 parts of ground beetle.
The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that the above embodiments and descriptions are merely illustrative of the principles of the present invention, and various changes and modifications may be made without departing from the spirit and scope of the invention, which is defined in the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.

Claims (3)

1. An application of astragalus and leech capsules in preparing a medicament for reducing essential hypertension and shrinking blood pressure is characterized in that: the astragalus and leech capsules are prepared from the following raw material medicines in parts by weight: 200 parts of astragalus, 80 parts of leech, 150 parts of peach kernel, 150 parts of fleece-flower root, 110 parts of curcuma zedoary, 110 parts of rhizoma sparganii, 125 parts of semen cassiae, 125 parts of hawthorn and 30 parts of ground beetle.
2. Use according to claim 1, characterized in that: the preparation method of the astragalus and leech capsules comprises the following steps:
firstly, weighing leech, rhizoma curcumae and rhizoma sparganii according to a proportion, and crushing the leech, the rhizoma curcumae and the rhizoma sparganii into fine powder;
weighing astragalus root, peach kernel, fleece-flower root, cassia seed, haw and ground beetle according to a proportion, adding water for decoction twice, adding 10 times of water for the first time and adding 8 times of water for the second time, decocting for 2 hours each time, merging decoction, filtering, and concentrating filtrate to thick paste with the relative density of 1.30-1.35;
step three, taking the fine powder in the step one, adding the thick paste in the step two, uniformly mixing, drying at 50-60 ℃, crushing and encapsulating;
the relative density is 1.30-1.35 at 80 ℃.
3. Use according to claim 2, characterized in that: the astragalus and leech capsule is one of granule, tablet, powder or pill.
CN202110641504.1A 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension Active CN113368209B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110641504.1A CN113368209B (en) 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110641504.1A CN113368209B (en) 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension

Publications (2)

Publication Number Publication Date
CN113368209A CN113368209A (en) 2021-09-10
CN113368209B true CN113368209B (en) 2023-07-11

Family

ID=77573061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110641504.1A Active CN113368209B (en) 2021-06-09 2021-06-09 New use of QIZHI Capsule in preparing medicine for treating essential hypertension

Country Status (1)

Country Link
CN (1) CN113368209B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1246030C (en) * 2001-06-15 2006-03-22 刘宇晖 Chouxue qing capsule for reducing blood viscosity

Also Published As

Publication number Publication date
CN113368209A (en) 2021-09-10

Similar Documents

Publication Publication Date Title
CN101554409B (en) Long pepper alkaloid and preparation method, preparation and application thereof
CN100455291C (en) Notoginseng medicine composition for treating cardiac and cerebral vascular diseases
WO2021179828A1 (en) Use of pharmaceutical composition in preparation of drug for treating acute lung injury
CN114246918B (en) Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof
EP4190342A1 (en) Traditional chinese medicine composition having mental relief and antidepressant effects and preparation method therefor
CN113368209B (en) New use of QIZHI Capsule in preparing medicine for treating essential hypertension
CN111840425A (en) Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof
CN1927324A (en) Preparation method of traditional medicine preparation for treating women&#39;s menoxenia
CN100467025C (en) Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels
CN101543574B (en) Chinese medicinal composition for treating pulmonary interstitial fibrosis
CN101347562A (en) Anti-depression medicament as well as preparation method and application thereof
CN104688723B (en) Application of icaritin in preparation of medicine for treating anemia
CN103349737B (en) Traditional Chinese medicine composite for treating headache and preparation method of traditional Chinese medicine composite
CN111166759A (en) A pharmaceutical composition for treating coronary heart disease
CN111068024A (en) Chinese medicine compound preparation and its preparing method
CN115337348B (en) Traditional Chinese medicine composition for treating heat-accumulation blood vessels
CN104042613B (en) A kind of composition and the purposes in medicine thereof
CN115227757B (en) Application of traditional Chinese medicine composition in preparation of antihypertensive drugs
CN115337347B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease
CN114767810B (en) Traditional Chinese medicine composition for treating acute lung injury as well as preparation method and application thereof
CN115671219B (en) Traditional Chinese medicine composition for treating gout and preparation method and application thereof
CN114028449B (en) Traditional Chinese medicine compound medicine for treating fatty liver disease
CN110215474B (en) Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof
CN101897927B (en) Medicinal composition for treating hyperthyroidism and preparation method thereof
CN100364596C (en) Compounded mongolia medicine for treating diabetes and preparing method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231030

Address after: 150025 North Nanjing Road, Limin Development Zone, Harbin City, Heilongjiang Province

Patentee after: Harbin traditional Chinese medicine four factory Co.,Ltd.

Address before: 150025 Harbin No.4 traditional Chinese Medicine Factory Co., Ltd., north of Nanjing Road, Limin Development Zone, Harbin, Heilongjiang Province

Patentee before: Che Yanning

TR01 Transfer of patent right